Re: Farmas USA
ARNA
Concesión de patente:
Announced today that the US Patent and Trademark Office granted Arena US Patent No. 9,169,213, entitled "Method of Weight Management," covering BELVIQ® (lorcaserin HCl) for chronic weight management.
"This patent is based on the discovery that achieving 5% weight loss with BELVIQ by Week 12 is a strong predictor of responses in weight loss at Week 52 of treatment," said Harry F. Hixson, Jr., Arena's interim Chief Executive Officer. "We expect that this method-of-treatment patent will provide additional support for exclusivity in the US until 2032, further strengthening our intellectual property position for BELVIQ."
«Después de nada, o después de todo/ supe que todo no era más que nada.»